Aurélie Dumont

567 total citations
9 papers, 229 citations indexed

About

Aurélie Dumont is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aurélie Dumont has authored 9 papers receiving a total of 229 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aurélie Dumont's work include Lung Cancer Treatments and Mutations (4 papers), Cancer-related Molecular Pathways (2 papers) and Cancer Genomics and Diagnostics (2 papers). Aurélie Dumont is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Cancer-related Molecular Pathways (2 papers) and Cancer Genomics and Diagnostics (2 papers). Aurélie Dumont collaborates with scholars based in France, Austria and Switzerland. Aurélie Dumont's co-authors include Francisco Cruzalegui, Guillem Rigaill, Sergio Roman‐Roman, Gordon C. Tucker, David Gentien, Bérengère Marty-Prouvost, Bruno Tesson, Virginie Maire, Leanne de Koning and Thierry Dubois and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Aurélie Dumont

9 papers receiving 228 citations

Peers

Aurélie Dumont

MB

ONCOL

CR

PRM

PFM

Louise D. Johnson United Kingdom

Ilianna Zoi Greece

Shiyi Yu China

Casey G. Langdon United States

Jia Bian China

Jakob Schöttle Germany

Marina Riggio Argentina

Anna A. Marusiak Poland

Linlin Mao China

Louise D. Johnson United Kingdom

Aurélie Dumont

154 ×1.0

MB

55 ×0.7

ONCOL

37 ×0.7

CR

47 ×1.1

PRM

30 ×0.9

PFM

Citations per year, relative to Aurélie Dumont Aurélie Dumont (= 1×) peers Louise D. Johnson

Countries citing papers authored by Aurélie Dumont

Since Specialization

Citations

This map shows the geographic impact of Aurélie Dumont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Dumont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Dumont more than expected).

Fields of papers citing papers by Aurélie Dumont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélie Dumont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Dumont. The network helps show where Aurélie Dumont may publish in the future.

Co-authorship network of co-authors of Aurélie Dumont

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Dumont. A scholar is included among the top collaborators of Aurélie Dumont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Dumont. Aurélie Dumont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Leblond, Pierre, Aurélie Dumont, Florence Gattacceca, et al.. (2022). Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis. Cancer Chemotherapy and Pharmacology. 90(1). 29–44. 4 indexed citations

2.

Cao, Christine Do, Aurélie Dumont, Y Robin, et al.. (2018). Tumeurs neuroendocrines primitives du sein : mythe ou réalité ? Une revue de la littérature. Bulletin du Cancer. 105(4). 431–439. 9 indexed citations

3.

Maubant, Sylvie, Tania Tahtouh, Virginie Maire, et al.. (2018). LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. Oncotarget. 9(32). 22586–22604. 20 indexed citations

4.

Dixmier, A., D. Debieuvre, J.B. Auliac, et al.. (2018). EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients. Annals of Oncology. 29. viii532–viii532. 1 indexed citations

5.

Rhun, Émilie Le, Nicolas Bertrand, Aurélie Dumont, et al.. (2017). Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. European Journal of Cancer. 87. 189–198. 33 indexed citations

6.

Dumont, Aurélie, Diane Pannier, Agnès Ducoulombier, et al.. (2015). ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors. SpringerPlus. 4(1). 327–327. 9 indexed citations

7.

Maire, Virginie, Céline Baldeyron, Marion Richardson, et al.. (2013). TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer. PLoS ONE. 8(5). e63712–e63712. 119 indexed citations

8.

Ducoulombier, Agnès, Aurélie Dumont, Emmanuelle Tresch, et al.. (2013). Association of ERCC1 (rs11615) and DNASE2B (rs3738573) polymorphisms with pathologic complete response to neoadjuvant chemotherapy for HER2-overexpressing breast cancer.. Journal of Clinical Oncology. 31(15_suppl). 536–536. 1 indexed citations

9.

Dumont, Aurélie, Audrey Sirvent, Michel Jan, et al.. (2011). Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells. PLoS ONE. 6(2). e17237–e17237. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact